Invicta Diagnostic Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Invicta Diagnostic Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹85
Per ShareLot Size
1600 Shares
Minimum Investment
₹1,36,000
Issue Size
₹28.12 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Invicta Diagnostic Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
90.52%
Promoter Holding (Post-Issue)
66.7%
Issue Type
Book Building - SME
ISIN
INE0XJ501010
About the Company
We are a diagnostic chain in Mumbai Metropolitan Region ("MMR") offering radiology and pathology solutions. We offer radiology and pathology testing services such as imaging (including radiology) and pathology/clinical laboratory to customers under the brand name "PC Diagnostics" through our operational network, which consists of 7 diagnostic centres and 1 centralised laboratory across MMR in the state of Maharashtra either directly or through our subsidiaries.
Industry Overview
Diagnostic services identify health conditions, ensuring diagnosis, treatment planning, and recovery. Catering to B2B (hospitals, clinics) and B2C (direct customers), these services are segmented into Pathology and Radiology. In India, the Radiology industry grew at a CAGR of 11.5% from 2020 to 2024 and is poised to grow from Rs. 407 billion in 2024 to Rs.868 billion by 2030 at a CAGR of 13.5%. In Maharashtra, it grew at a CAGR of 10.7% from 2020 to 2024 and is poised to grow from Rs. 15.04 billion in 2024 to Rs. 31.4 billion by 2030 at a CAGR of 13.1%.
Company History
Our Company was incorporated as Limited Liability Partnership under the name "Invicta Diagnostic LLP" under the provisions of the Limited Liability Partnership Act, 2008 vide Certificate of Incorporation dated January 22, 2021 issued by Assistant Registrar of Companies, Central Registration Centre. Further, Invicta Diagnostic LLP was converted into a private limited company "Invicta Diagnostic Private Limited" pursuant to the provisions of Chapter XXI of the Companies Act, 2013 and a fresh Certificate of Incorporation dated December 01, 2023 was issued by Assistant Registrar of Companies, Central Registration Centre. Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a resolution passed in the extraordinary general meeting of our Shareholders held on April 20, 2024 and the name of our Company was changed to "Invicta Diagnostic Limited" and a fresh certificate of incorporation dated July 02, 2024 was issued to our Company by the Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies, Central Processing Centre. The Corporate Identification Number of our Company is U86100MH2023PLC414723.
Products & Services
- The Company is a diagnostic chain in Mumbai Metropolitan Region ("MMR") offering radiology and pathology solutions.
Growth Strategy
- Expanding geographic footprint across the Maharashtra.
- Deepen footprint in our core markets and Physician Outreach.
- Branding and Advertising.
- Supplement Organic Growth with Acquisitions.
Customer Base
Wholesaler and Retailer
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offering of 33,08,800 equity shares of face value of Rs. 10/- each ("Equity Shares") for cash at a price of Rs. 85/- per equity share (including a premium of Rs. 75/- per equity share) ("Issue price") aggregating to Rs. 28.12 crores ("the Issue"). The issue will constitute 26.32 % of the post-issue paid up equity share capital of the company. The issue includes a reservation of 1,66,400 equity shares aggregating to Rs. 1.41 crores (constituting up to 1.32 % of the post issue paid-up equity share capital of the company) for subscription by market maker ("Market Maker Reservation Portion"). The issue less the market maker reservation portion is hereinafter referred to as the "Net Issue". The issue and the net issue will constitute 26.32 % and 25.00 % respectively, of the post-issue paid-up equity share capital of the company. Price Band: Rs. 85/- for equity share of face value of Rs. 10 each. The floor price is 8.50 times times the face value times of the face value of the equity shares. Bids can made for a minimum of 3,200 equity shares and in multiples of 1,600 equity shares thereafter.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Expanding presence in Mumbai Metropolitan Region ("MMR") specifically in radiology sector.
- Diagnostics provider that offers one-stop solution at affordable price.
- Technical capability and technology with IT infrastructure.
- Dedicated management team with significant industry experience.
- Implementation of Hub and Spoke Model.
- Its business and prospects may be adversely affected if the company is unable to maintain and grow its brand name and brand image.
- Any interruptions at its flagship centre and other diagnostic centres may affect the company ability to process diagnostic tests, which in turn may adversely affect its business, results of operations and financial condition.
- Concentrated emphasis on radiology services also exposes it to substantial risks that could adversely impact its operations, financial performance, and long-term growth prospects.
- The company operations are concentrated in Mumbai Metropolitan Region ("MMR"), and any loss of business in such region could have an adverse effect on its business, results of operations and financial condition.
- Its ability to remain competitive may be adversely affected by technological advancements, innovations in diagnostic testing and its ability to access such technology.